Study of Karenitecin (BNP1350) in Patients With Brain Tumors

NCT00062478 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Brain Neoplasms
Malignant Neoplasms, Brain
Brain Tumors

Interventions

DRUG: Karenitecin (BNP1350)

Sponsor

BioNumerik Pharmaceuticals, Inc.

Collaborators

[object Object]